Should you build or buy Real-World Data (RWD) / Real-World Evidence Analytics Platform?
Real-World Data (RWD) / Real-World Evidence Analytics Platforms combine licensed patient-level datasets — insurance claims, electronic health records, specialty registries — with analytics tooling for study design, cohort selection, propensity scoring, and survival analysis, primarily to support market access submissions, HEOR studies, and post-approval safety monitoring.
Copy reviewed 2026-09-19 · Research revision 2026-09-06
License the data. Think hard before licensing the platform. OMOP CDM and the OHDSI/ATLAS stack have matured into genuine production infrastructure, and the pharma companies with the most serious RWE programs have built on them rather than buying an analytics layer: Bayer's FOUNTAIN runs eight CDM-mapped sources across seven countries with federated execution, J&J's ASSURE is a standardised active-safety-surveillance framework on an OMOP network with its own phenotype development and validity diagnostics, Janssen's epidemiology analytics reaches 400M+ patient records using ATLAS for cohort rules and distributed study execution, and UCB paid to extend ATLAS rather than replace it. What none of them rebuilt is the data - claims, EHR, oncology, lab and registry assets from IQVIA, Komodo, Optum, Flatiron, TriNetX and Datavant stay licensed, and the linkage and specialty abstraction stay bought. The asset worth compounding is the phenotype library and the standardised data model, because those carry across every study you run and no vendor contract takes them with it. Keep a vendor or CRO on call for hard linkage and regulatory-grade studies where speed matters.
Build it, buy it, or bridge?
When building makes sense
The build case exists, but it's narrower than in most software categories. If a team already has licensed access to claims data from IQVIA, Komodo, or Datavant, building the analytics layer on top is supported by mature statistical tooling but still needs data and methodological validation — propensity scoring, survival analysis, and HEOR study design are well-understood statistical methods with mature implementations in R and Python. Statistical teams with biostatistics depth can own their study design tooling and visualization stack without being constrained by a vendor's interface. What AI has done is lower the cost of this analytics layer further — custom cohort selection logic and covariate adjustment pipelines that once required significant bespoke engineering now have solid open-source starting points. Data access and sound analysis are separate requirements. If a team has already negotiated the underlying data agreements and doesn't want to pay a second time for an analytics wrapper they could build themselves, the build case is real.
When buying makes sense
Buying makes the clearest sense when the goal is to run RWE studies without spending time negotiating raw data agreements separately from the analytics platform. Platforms like Aetion, Flatiron, and IQVIA's RWE suite bundle the licensed patient-level data and the analytics environment in a single contract — and the licensed data is the product that matters. The analytic methods (propensity scoring, survival analysis, HEOR endpoints) are standardized across pharma; buyers should examine how each vendor implements and validates them for the intended use. For organizations that need to generate evidence packages for market access decisions on tight timelines, the vendor's combination of compliant data, pre-validated methods, and regulatory familiarity is worth paying for. An internal analytics build needs a viable data-access plan, because no amount of analytics engineering replicates a claims dataset.
The desk read
RWE platforms bundle two distinct things: licensed patient-level data assets and an analytics layer on top of them. IQVIA, Komodo Health, Flatiron, and Datavant have built their positions on the data, not the analytics. Propensity scoring, survival analysis, and HEOR study design are standardized analytic methods, and teams with statistical depth can build those layers themselves. The blocking factor is the underlying claims and EHR datasets, which no internal team can replicate.
Buying earns its keep when you need the licensed data and an analytics environment in a single contract and don't want to negotiate raw data agreements separately. The build case emerges at the analytics wrapper level, where teams that already license RWD from Aetion or TriNetX want more control over study design tooling and visualization without being locked into the vendor's interface. What AI has changed is the cost of the analytics layer, not the data layer, and that's where the economics are shifting.
Frequently asked
What is a Real-World Data (RWD) / Real-World Evidence Analytics Platform?
Real-World Data / Real-World Evidence Analytics Platforms combine licensed patient-level datasets — insurance claims, electronic health records, specialty registries — with analytics tooling for study design, cohort selection, propensity scoring, and survival analysis, primarily to support market access submissions, HEOR studies, and post-approval safety monitoring.
When does building a Real-World Data / Real-World Evidence Analytics Platform make sense?
The build case exists, but it's narrower than in most software categories. If a team already has licensed access to claims data from IQVIA, Komodo, or Datavant, building the analytics layer on top is supported by mature statistical tooling but still needs data and methodological validation — propensity scoring, survival analysis, and HEOR study design are well-understood statistical methods with mature implementations in R and Python. Statistical teams with biostatistics depth can own their study design tooling and visualization stack without being constrained by a vendor's interface. What AI has done is lower the cost of this analytics layer further — custom cohort selection logic and covariate adjustment pipelines that once required significant bespoke engineering now have solid open-source starting points. Data access and sound analysis are separate requirements. If a team has already negotiated the underlying data agreements and doesn't want to pay a second time for an analytics wrapper they could build themselves, the build case is real.
When does buying a Real-World Data / Real-World Evidence Analytics Platform make sense?
Buying makes the clearest sense when the goal is to run RWE studies without spending time negotiating raw data agreements separately from the analytics platform. Platforms like Aetion, Flatiron, and IQVIA's RWE suite bundle the licensed patient-level data and the analytics environment in a single contract — and the licensed data is the product that matters. The analytic methods (propensity scoring, survival analysis, HEOR endpoints) are standardized across pharma; buyers should examine how each vendor implements and validates them for the intended use. For organizations that need to generate evidence packages for market access decisions on tight timelines, the vendor's combination of compliant data, pre-validated methods, and regulatory familiarity is worth paying for. An internal analytics build needs a viable data-access plan, because no amount of analytics engineering replicates a claims dataset.
What are the main Real-World Data / Real-World Evidence Analytics Platform vendors?
Representative vendors include Axtria, Cognotekt, IQVIA (RWE), Aetion, Datavant / TriNetX, Flatiron Health. B4 Pro includes the category score and the full vendor list.
What is the difference between RWD and RWE?
Real-World Data (RWD) refers to the raw patient-level datasets — claims, EHR records, registries. Real-World Evidence (RWE) is what you generate by analyzing that data to answer a clinical or economic question. The platforms in this category typically provide both: the data access and the analytical environment to turn data into evidence.